RHYTHM PHARMACEUTICALS, INC.

RYTM

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Dec 15, 2025

Drug Pipeline

Drug Name	Phase	Indication	Designations
Placebo	Phase 3	Obesity	-
Setmelanotide 2 mg	Phase 3	Bardet-Biedl Syndrome	-
Setmelanotide	Phase 2	Genetic Obesity	-
LB54640	Phase 2	Hypothalamic Obesity	-

Catalyst Timeline

6 upcoming, 0 past

⭐Phase 3Next

Setmelanotide Phase 3 Results Expected

December 2025~Setmelanotide

Primary completion for Setmelanotide trial (NCT05093634) in Obesity

Source

⭐Phase 3

Placebo Phase 3 Results Expected

December 2025~Placebo

Primary completion for Placebo trial (NCT05093634) in Obesity

Source

Phase 2

LB54640 Phase 2 Results Expected

Jan 31, 2026LB54640

Primary completion for LB54640 trial (NCT06046443) in Hypothalamic Obesity

Source

⭐Phase 3

Setmelanotide Phase 3 Results Expected

Sep 30, 2026Setmelanotide

Primary completion for Setmelanotide trial (NCT06760546) in Hypothalamic Obesity

Source

⭐Phase 3

Placebo Phase 3 Results Expected

Sep 30, 2026Placebo

Primary completion for Placebo trial (NCT06760546) in Hypothalamic Obesity

Source

Phase 2

Setmelanotide Phase 2 Results Expected

Oct 31, 2026Setmelanotide

Primary completion for Setmelanotide trial (NCT06772597) in Prader-Willi Syndrome

Source

Regulatory Approvals

RYTM News

RHYTHM PHARMACEUTICALS, INC.

RYTM

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Dec 15, 2025

Drug Pipeline

Drug Name	Phase	Indication	Designations
Placebo	Phase 3	Obesity	-
Setmelanotide 2 mg	Phase 3	Bardet-Biedl Syndrome	-
Setmelanotide	Phase 2	Genetic Obesity	-
LB54640	Phase 2	Hypothalamic Obesity	-

Catalyst Timeline

6 upcoming, 0 past

⭐Phase 3Next

Setmelanotide Phase 3 Results Expected

December 2025~Setmelanotide

Primary completion for Setmelanotide trial (NCT05093634) in Obesity

Source

⭐Phase 3

Placebo Phase 3 Results Expected

December 2025~Placebo

Primary completion for Placebo trial (NCT05093634) in Obesity

Source

Phase 2

LB54640 Phase 2 Results Expected

Jan 31, 2026LB54640

Primary completion for LB54640 trial (NCT06046443) in Hypothalamic Obesity

Source

⭐Phase 3

Setmelanotide Phase 3 Results Expected

Sep 30, 2026Setmelanotide

Primary completion for Setmelanotide trial (NCT06760546) in Hypothalamic Obesity

Source

⭐Phase 3

Placebo Phase 3 Results Expected

Sep 30, 2026Placebo

Primary completion for Placebo trial (NCT06760546) in Hypothalamic Obesity

Source

Phase 2

Setmelanotide Phase 2 Results Expected

Oct 31, 2026Setmelanotide

Primary completion for Setmelanotide trial (NCT06772597) in Prader-Willi Syndrome

Source

Regulatory Approvals

RYTM News